Linea 1
LINi001-A
General
Cell Line |
|
| hPSCreg name | LINi001-A |
| Cite as: | LINi001-A |
| Alternative name(s) |
Linea 1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 7th December 2025 |
| User feedback | |
Provider |
|
| Generator |
LineaBio (LIN)
Contact:
LineaBio (LIN) |
| Owner | LineaBio (LIN) |
| Distributors | |
| Derivation country | Canada |
External Databases |
|
| BioSamples | SAMEA120784092 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 30-34 |
| Ethnicity |
Self-declared race/ethnicity = Caucasian Ancestry = 100% European |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
External Databases (Donor) |
|
| BioSamples | SAMEA120784093 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | Yes |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | No |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Alpha IRB |
| Approval number | September 29, 2021 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | No |
| Do you have obligations to third parties in regard to the use of the cell line? | Yes |
| Please describe: | Use of the cell line is subject to third-party intellectual property rights. iPS Academia Japan holds the licensing rights for the Yamanaka reprogramming factors, and ID Pharma Co. Ltd. holds the rights associated with the Sendai virus reprogramming system. |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Thermo Fisher |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | No additional constraints beyond the third-party licensing obligations already noted for the Yamanaka factors (iPS Academia Japan) and the Sendai reprogramming system (ID Pharma Co. Ltd.). |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
| Source cell type (free text) | CD34+ |
| Age of donor (at collection) | 30-34 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Vector map | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
Yes |
Culture Conditions
| Surface coating | Laminin |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
CTS™ Versene™ Solution
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| TRA 1-60 |
Yes |
Morphology pictures
Figure 1. Linea 1 (LINi001-A) Human Pluripotent Stem Cells Demonstrate High-Quality Morphology in Routine Culture.
Cryopreserved cells from line Linea 1 (LINi001-A) were thawed and maintained in mTeSR1 on Biolaminin 521 CTG (CTG521). (A,B) Colonies show the expected migratory behaviour on Biolaminin 521, with more irregular borders and looser packing early in culture. Cell density and border definition increase as confluence is reached. (C) Cells retain prominent nucleoli and high nuclear-to-cytoplasmic ratios.
Cryopreserved cells from line Linea 1 (LINi001-A) were thawed and maintained in mTeSR1 on Biolaminin 521 CTG (CTG521). (A,B) Colonies show the expected migratory behaviour on Biolaminin 521, with more irregular borders and looser packing early in culture. Cell density and border definition increase as confluence is reached. (C) Cells retain prominent nucleoli and high nuclear-to-cytoplasmic ratios.
Differentiation Potency
In vitro directed differentiation
Protocol or reference
10000003448-PIS_02.pdf
STEMdiff Definitive Endoderm Kit Product Information Sheet
In vitro directed differentiation
Protocol or reference
10000000175-PIS_01.pdf
STEMdiff Mesoderm Induction Medium Product Information Sheet
In vitro directed differentiation
Protocol or reference
10000000231-PIS_07.pdf
STEMdiff SMADi Neural Induction Kit Product Information Sheet
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
Genome sequencing
SNP typing array
Array CGH
|
Login to share your feedback, experiences or results with the research community.